Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,494 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intervention 2 - Placebo Clear all

Conditions: Contraceptive Devices, Long-Acting Reversible Contraception, Analgesia, Adolescent Health, Gynecology
Interventions: Nitrous oxide gas for inhalation, Oxygen Gas for Inhalation; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 14 Years to 24 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Myocardial Bridging
Interventions: Nebivolol, Diltiazem, Placebo; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: HIV Infections
Interventions: env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant, Placebo; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions: Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer
Interventions: Vitamin E; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Obstructive Sleep Apnea, Nasal Congestion, Sinus Congestion
Interventions: Thermosmart & placebo, Placebo Device & Nasacort, Placebo Arm; Drug · Device
Lead sponsor: Clayton Sleep Insititute; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Myositis
Interventions: Nipocalimab, Placebo, Glucocorticoids; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 19
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more

Conditions: Pediatric Burns
Interventions: magnesium sulfate, Normal Saline (0.9% NaCl); Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 3 Years to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Neurogenic Orthostatic Hypotension
Interventions: Sinosuidal Galvanic Vestibular Stimulation, Placebo; Device
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Smoking, Nicotine Dependence, Mental Disorders
Interventions: Cognitive / Motivational Individual Sessions, Attention Control Individual Sessions, Nicotine Patch, Group Curriculum; Behavioral · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 99 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Sleep, THC, Marijuana, Cannabis
Interventions: Dronabinol; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 34 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: COPD, Emphysema, Emphysema or COPD
Interventions: dual anti-platelet therapy, Placebo; Combination Product · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dietary Modification, Cardiovascular Disease
Interventions: Chlorophyll complex, Standard Process, Betatene, sold as "Full Spectrum Carotenoid Complex", Small carotenoid-rich meals, Placebo; Dietary Supplement · Other
Lead sponsor: Bastyr University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Kenmore, Washington • Seattle, Washington

Conditions: Translational Electrophysiology
Interventions: Methylphenidate; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 222 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Postoperative Nausea and Vomiting
Interventions: Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: Up to 16 Years
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 12
States / cities: Florence, Alabama • Sheffield, Alabama • Washington D.C., District of Columbia + 9 more

Conditions: Excessive Daytime Sleepiness, Narcolepsy
Interventions: Placebo, PF-03654746; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 15 more

Conditions: Chronic Pain
Interventions: Mindfulness-Based Stress Reduction (MBSR), Open-Label Placebo (OLP), MBSR+OLP; Behavioral · Other
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Phoenix, Arizona

Conditions: Asthma
Interventions: MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years and older
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 29
States / cities: Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more

Conditions: Diabetic Peripheral Neuropathy
Interventions: Erchonia FX-635, Placebo Laser; Device
Lead sponsor: Erchonia Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Mesa, Arizona • Costa Mesa, California • Hialeah, Florida + 1 more

Conditions: Post Traumatic Stress Disorder
Interventions: Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo, Intervention C Daridorexant, Intervention C Placebo, Intervention D SLS-002, Intervention D Placebo; Drug
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more

Conditions: Acute Myocardial Infarction, Congestive Heart Failure, ST-Elevation Myocardial Infarction
Interventions: IK-5001, Saline Solution; Device
Lead sponsor: Bellerophon BCM LLC; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 16
States / cities: Birmingham, Alabama • Torrance, California • Washington D.C., District of Columbia + 13 more

Conditions: Ketogenic Dieting
Interventions: Carbohydrate Supplement (Carb10), Diet, Exercise; Dietary Supplement · Other
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Denton, Texas

Conditions: Post-Operative Pain, Chronic
Interventions: Adductor Canal Block, Intra-articular Injection; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Interventions: Satralizumab, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 11
States / cities: Birmingham, Alabama • Newport Beach, California • San Francisco, California + 7 more

Search by objective public record fields.

Nitrous Oxide for Pain Management During IUD Insertion in Nulliparous Adolescent Women

Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer

Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

Magnesium Sulfate in Pediatric Burn Dressing Changes

Sinusoidal Galvanic Vestibular Stimulation for Neurogenic Orthostatic Hypotension / Syncope

Helping Those With Mental Illness Quit Smoking

Tetrahydrocannabinol (THC) and Sleep

Anti-Platelets in Chronic Obstructive Pulmonary Disease

Feeding the Rainbow to Investigate Endothelial Dysfunction

Novel Cross-Species Neurophysiological Assays of Reward and Cognitive Domains

Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

Mindfulness And Placebo for Pain (MAPP) Study

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

An Evaluation of the Effect of Low Level Laser Therapy on Diabetic Peripheral Neuropathy Pain

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction

Determining the Ergogenic Effects of Carb10™ Supplementation on Carbohydrate-Rich and Carbohydrate-Restricted Diets

Intra-articular Analgesia Versus Adductor Canal Block for Arthroscopic Knee Surgery

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis